Home › Research › Biomarkers
Blutbiomarker für Morbus Alzheimer
Susanne Krome. DMW - Deutsche Medizinische Wochenschrift, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Eine von 5 Frauen und einer von 10 Männern entwickeln eine Demenz vom Alzheimer-Typ, erläutern Palmqvist et al. zu Beginn ihrer Studie [1]. Extrazelluläre β-Amyloid-Ablagerungen und intrazellulär angereichertes Tau-Protein sind Schlüsselelemente in der Pathophysiologie. Deren Bestimmung im Liquor hat sich etabliert. Die schwedische Arbeitsgruppe stellt einen Bluttest mit der Kombination aus prozentualem phosphoryliertem Tau217 (p-tau217) und der Aß42/Aß40-Ratio (APS2) vor. Publication History Article published online: 14 January 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Key findings
- Extrazelluläre β-Amyloid-Ablagerungen und intrazellulär angereichertes Tau-Protein sind Schlüsselelemente in der Pathophysiologie.
- Deren Bestimmung im Liquor hat sich etabliert.
- Die schwedische Arbeitsgruppe stellt einen Bluttest mit der Kombination aus prozentualem phosphoryliertem Tau217 (p-tau217) und der Aß42/Aß40-Ratio (APS2) vor.
- Publication History Article published online: 14 January 2025 © 2025.
- Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Why it matters
A Swedish group presents a blood test combining percentage phosphorylated tau217 and the Aβ42/Aβ40 ratio (APS2) for Alzheimer's disease. This is a diagnostic approach; the text does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 24 of the 93 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (DMW - Deutsche Medizinische Wochenschrift) |
| Journal's citation record | 1 / 4 | DMW - Deutsche Medizinische Wochenschrift: journal h-index 94 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 24 of the 93 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Krome, S. (2025). Blutbiomarker für Morbus Alzheimer. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/a-2422-1921
Vancouver
Krome S. Blutbiomarker für Morbus Alzheimer. DMW - Deutsche Medizinische Wochenschrift. 2025. doi:10.1055/a-2422-1921.
BibTeX
@article{krome2025-296a87ae,
author = {Krome, Susanne},
title = {{Blutbiomarker für Morbus Alzheimer}},
journal = {DMW - Deutsche Medizinische Wochenschrift},
year = {2025},
doi = {10.1055/a-2422-1921},
url = {https://doi.org/10.1055/a-2422-1921}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.